Business Wire

CA-ANDERSEN-GLOBAL

31.8.2022 13:58:34 CEST | Business Wire | Pressemeddelelse

Del
Andersen Global udvider sin tilstedeværelse i Afrika med yderligere dækning i Tanzania

Andersen Global fortsætter med at tilføje dybde til sin Afrika-platform gennem en samarbejdsaftale med advokatfirmaet Lawhill and Co. Advocates i Tanzania.

Lawhill and Co. Advocates er baseret i Dar es Salaam og er grundlagt i 2019. Virksomheden arbejder sammen med lokale og internationale kunder, herunder selskaber og internationale konsulentorganisationer. Under ledelse af administrerende partner Hadija Kinyaka tilbyder virksomheden skatte-, selskabs- og erhvervsretlige tjenester samt strategiske civilretssager, der spænder over forskellige brancher, herunder telekommunikation, energi og infrastruktur, naturressourcer, bank og finans, international handel samt beskæftigelse og immigration.

”Vores team af skatte- og erhvervsfolk stræber efter at sætte standarden for kvalitetsservice på tværs af alle brancher og at være en virksomhed, der udbyder tjenester til diverse forretningsbehov på ét sted,” siger Hadija. ”De sidste par år har været en transformationsperiode for vores virksomhed, og dette samarbejde med Andersen Global styrker vores evne til at levere den bedste service til vores lokale, regionale og internationale kunder. Dette samarbejde hjælper reelt set virksomheden med at opfylde sin vision om at forblive et af de førende advokatfirmaer inden for skatte- og selskabsret i Tanzania og er en vigtig milepæl på vejen mod at opnå global rækkevidde.”

”Hadija og hendes team udviser konsekvent den højeste professionelle standard og har etableret en virksomhed, der er baseret på gennemsigtighed og ledelse,” tilføjer Andersen Globals bestyrelsesformand og CEO Mark Vorsatz. ”I takt med at vi fortsætter med at etablere en stærk tilstedeværelse i Afrika-regionen vil Lawhill and Co. Advocates give værdifuld indsigt i det tanzaniske marked og arbejde synergetisk med de omkringliggende medlems- og samarbejdsvirksomheder for at levere problemfri service globalt.”

Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer, som består af skatte- og juraeksperter fra hele verden. Siden stiftelsen i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC har Andersen Global nu over 12.000 eksperter globalt og er repræsenteret på mere end 380 lokaliteter via sine medlems- og samarbejdsvirksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220830005246/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye